Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Regeneron Pharmaceuticals, Inc. (REGN) since 2005 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Regeneron Pharmaceuticals, Inc.. (See page 1 of this report.) Table 2 shows the detailed insider transactions. This company's CIK number is 872589.
Total stock buying since 2005: $2,475,753,844.
Total stock sales since 2005: $14,586,084,237.
Total stock option exercises since 2005: $1,313,104,322.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2024 | 0 | $0 | 210,364 | $207,522,474 | 616,322 | $254,112,622 |
| 2023 | 0 | $0 | 95,808 | $78,349,729 | 273,334 | $75,352,970 |
| 2022 | 0 | $0 | 209,705 | $142,182,035 | 469,330 | $145,352,340 |
| 2021 | 0 | $0 | 563,365 | $351,623,746 | 2,003,096 | $333,732,044 |
| 2020 | 0 | $0 | 24,311,062 | $12,445,396,750 | 1,955,372 | $164,839,706 |
| 2019 | 0 | $0 | 416,206 | $143,310,975 | 917,671 | $23,311,139 |
| 2018 | 0 | $0 | 427,003 | $148,810,340 | 927,576 | $18,552,974 |
| 2017 | 462,141 | $212,021,764 | 137,384 | $65,407,790 | 900,886 | $27,301,249 |
| 2016 | 148,669 | $62,482,433 | 20,663 | $8,394,544 | 774,368 | $17,691,794 |
| 2015 | 260,466 | $131,463,987 | 420,930 | $219,457,542 | 678,280 | $37,168,578 |
| 2014 | 6,498,829 | $2,040,580,495 | 592,551 | $211,494,397 | 1,689,378 | $74,072,416 |
| 2013 | 0 | $0 | 979,452 | $254,768,275 | 1,464,593 | $33,265,521 |
| 2012 | 0 | $0 | 1,215,019 | $159,380,088 | 2,319,093 | $46,475,631 |
| 2011 | 0 | $0 | 729,476 | $37,856,945 | 1,678,597 | $36,895,258 |
| 2010 | 1,034,901 | $28,971,078 | 317,918 | $9,118,977 | 332,278 | $5,014,862 |
| 2009 | 12,500 | $234,087 | 114,271 | $2,249,950 | 651,002 | $5,760,483 |
| 2008 | 0 | $0 | 156,479 | $3,272,738 | 500,195 | $4,022,051 |
| 2007 | 0 | $0 | 224,867 | $5,157,435 | 316,441 | $3,033,949 |
| 2006 | 0 | $0 | 443,650 | $8,648,660 | 580,125 | $5,427,485 |
| 2005 | 0 | $0 | 7,562,667 | $83,680,847 | 135,000 | $1,721,250 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2020-06-11 | Landry Robert E (EVP Finance CFO) | Sale | 988 | 615.59 | 608,199 |
| 2020-06-10 | Zoghbi Huda Y (Director) | Sale | 1,706 | 611.13 | 1,042,582 |
| 2020-06-10 | Zoghbi Huda Y (Director) | Option Ex | 1,706 | 391.92 | 668,615 |
| 2020-06-10 | Landry Robert E (EVP Finance CFO) | Option Ex | 3,500 | 272.70 | 954,450 |
| 2020-06-09 | Landry Robert E (EVP Finance CFO) | Sale | 4,271 | 606.43 | 2,590,066 |
| 2020-06-09 | Sanofi | Sale | 120,234 | 597.48 | 71,837,410 |
| 2020-06-08 | Landry Robert E (EVP Finance CFO) | Option Ex | 15,500 | 272.70 | 4,226,850 |
| 2020-06-08 | Goldstein Joseph L (Director) | Sale | 10,838 | 593.33 | 6,430,467 |
| 2020-06-08 | Goldstein Joseph L (Director) | Option Ex | 10,838 | 413.33 | 4,479,670 |
| 2020-06-05 | Bassler Bonnie L (Director) | Sale | 2,559 | 600.00 | 1,535,400 |
| 2020-06-05 | Bassler Bonnie L (Director) | Option Ex | 2,559 | 391.92 | 1,002,923 |
| 2020-06-01 | Ryan Arthur F (Director) | Sale | 100 | 603.00 | 60,299 |
| 2020-05-29 | Sing George L (Director) | Sale | 1,000 | 596.51 | 596,510 |
| 2020-05-29 | Sanofi | Sale | 22,821,451 | 509.85 | 11,635,516,792 |
| 2020-05-28 | Goldstein Joseph L (Director) | Sale | 1,000 | 578.94 | 578,940 |
| 2020-05-28 | Sing George L (Director) | Sale | 1,000 | 579.00 | 579,000 |
| 2020-05-21 | Vagelos P Roy (Chairman of the Board) | Sale | 149,594 | 572.18 | 84,754,189 |
| 2020-05-20 | Vagelos P Roy (Chairman of the Board) | Option Ex | 312,500 | 30.63 | 9,571,875 |
| 2020-05-15 | Larosa Joseph J (EVP General Counsel and Secret) | Sale | 8,380 | 572.00 | 4,793,360 |
| 2020-05-14 | Larosa Joseph J (EVP General Counsel and Secret) | Option Ex | 18,311 | 59.20 | 1,084,011 |
| 2020-05-13 | Sing George L (Director) | Sale | 5,000 | 580.00 | 2,900,000 |
| 2020-05-13 | Sing George L (Director) | Option Ex | 5,000 | 33.42 | 167,100 |
| 2020-05-12 | Schleifer Leonard S (President & CEO) | Sale | 150,922 | 567.50 | 85,647,480 |
| 2020-05-11 | Stahl Neil (EVP Research and Development) | Sale | 5,305 | 568.97 | 3,018,385 |
| 2020-05-11 | Sing George L (Director) | Sale | 850 | 575.00 | 488,750 |
| 2020-05-11 | Schleifer Leonard S (President & CEO) | Option Ex | 312,500 | 30.63 | 9,571,875 |
| 2020-05-08 | Stahl Neil (EVP Research and Development) | Option Ex | 12,500 | 52.03 | 650,375 |
| 2020-05-07 | Zoghbi Huda Y (Director) | Sale | 5,118 | 567.43 | 2,904,116 |
| 2020-05-07 | Zoghbi Huda Y (Director) | Option Ex | 5,118 | 391.92 | 2,005,846 |
| 2020-05-07 | Van Plew Daniel P (EVP & General Mgr Industrial O) | Sale | 39,583 | 563.01 | 22,285,466 |
| 2020-05-07 | Brown Michael S (Director) | Sale | 1,809 | 562.00 | 1,016,658 |
| 2020-05-06 | Tessier-lavigne Marc (Director) | Sale | 15,000 | 564.38 | 8,465,730 |
| 2020-05-06 | Tessier-lavigne Marc (Director) | Option Ex | 15,000 | 177.82 | 2,667,300 |
| 2020-05-06 | Van Plew Daniel P (EVP & General Mgr Industrial O) | Option Ex | 85,579 | 52.03 | 4,452,675 |
| 2020-05-06 | Goldstein Joseph L (Director) | Sale | 2,000 | 560.00 | 1,120,000 |
| 2020-05-06 | Ryan Arthur F (Director) | Sale | 50,124 | 549.34 | 27,535,168 |
| 2020-05-06 | Ryan Arthur F (Director) | Option Ex | 50,124 | 359.12 | 18,000,731 |
| 2020-05-06 | Brown Michael S (Director) | Option Ex | 5,470 | 325.18 | 1,778,734 |
| 2020-05-01 | Ryan Arthur F (Director) | Sale | 100 | 522.39 | 52,239 |
| 2020-04-20 | Landry Robert E (EVP Finance CFO) | Sale | 3,250 | 567.79 | 1,845,330 |
| 2020-04-20 | Larosa Joseph J (EVP General Counsel and Secret) | Sale | 5,300 | 567.48 | 3,001,773 |
| 2020-04-17 | Landry Robert E (EVP Finance CFO) | Sale | 991 | 555.42 | 550,424 |
| 2020-04-17 | Landry Robert E (EVP Finance CFO) | Option Ex | 12,500 | 272.70 | 3,408,750 |
| 2020-04-17 | Larosa Joseph J (EVP General Counsel and Secret) | Sale | 2,267 | 555.40 | 1,259,087 |
| 2020-04-17 | Larosa Joseph J (EVP General Counsel and Secret) | Option Ex | 11,622 | 59.20 | 688,022 |
| 2020-04-16 | Landry Robert E (EVP Finance CFO) | Option Ex | 4,000 | 272.70 | 1,090,800 |
| 2020-04-16 | Larosa Joseph J (EVP General Counsel and Secret) | Option Ex | 5,000 | 59.20 | 296,000 |
| 2020-04-15 | Landry Robert E (EVP Finance CFO) | Sale | 853 | 519.71 | 443,315 |
| 2020-04-15 | Larosa Joseph J (EVP General Counsel and Secret) | Sale | 2,262 | 519.40 | 1,174,885 |
| 2020-04-14 | Landry Robert E (EVP Finance CFO) | Option Ex | 3,500 | 272.70 | 954,450 |
| 2020-04-14 | Larosa Joseph J (EVP General Counsel and Secret) | Option Ex | 5,000 | 59.20 | 296,000 |
| 2020-04-14 | Stahl Neil (EVP Research and Development) | Sale | 5,497 | 520.68 | 2,862,177 |
| 2020-04-13 | Landry Robert E (EVP Finance CFO) | Sale | 828 | 509.95 | 422,241 |
| 2020-04-13 | Stahl Neil (EVP Research and Development) | Option Ex | 13,079 | 52.03 | 680,500 |
| 2020-04-09 | Landry Robert E (EVP Finance CFO) | Option Ex | 3,500 | 272.70 | 954,450 |
| 2020-04-07 | Landry Robert E (EVP Finance CFO) | Sale | 696 | 500.15 | 348,107 |
| 2020-04-06 | Landry Robert E (EVP Finance CFO) | Option Ex | 3,000 | 272.70 | 818,100 |
| 2020-04-03 | Landry Robert E (EVP Finance CFO) | Sale | 683 | 494.85 | 337,983 |
| 2020-04-02 | Landry Robert E (EVP Finance CFO) | Sale | 1,353 | 492.69 | 662,452 |
| 2020-04-02 | Landry Robert E (EVP Finance CFO) | Option Ex | 3,000 | 272.70 | 818,100 |
| 2020-04-02 | Larosa Joseph J (EVP General Counsel and Secret) | Sale | 6,797 | 490.97 | 3,337,136 |
| 2020-04-01 | Fenimore Christopher R. (VP Controller) | Sale | 1,200 | 487.35 | 584,823 |
| 2020-04-01 | Fenimore Christopher R. (VP Controller) | Option Ex | 1,200 | 30.63 | 36,756 |
| 2020-04-01 | Landry Robert E (EVP Finance CFO) | Sale | 600 | 486.54 | 291,924 |
| 2020-04-01 | Landry Robert E (EVP Finance CFO) | Option Ex | 6,000 | 272.70 | 1,636,200 |
| 2020-04-01 | Larosa Joseph J (EVP General Counsel and Secret) | Option Ex | 15,000 | 59.20 | 888,000 |
| 2020-04-01 | Ryan Arthur F (Director) | Sale | 100 | 486.06 | 48,606 |
| 2020-03-30 | Ryan Arthur F (Director) | Sale | 100 | 465.94 | 46,594 |
| 2020-03-10 | Yancopoulos George (President and Chief Scientific) | Sale | 117,815 | 473.68 | 55,807,080 |
| 2020-03-09 | Yancopoulos George (President and Chief Scientific) | Option Ex | 246,736 | 30.63 | 7,557,523 |
| 2020-03-09 | Goldstein Joseph L (Director) | Sale | 2,000 | 474.28 | 948,554 |
| 2020-03-09 | Goldstein Joseph L (Director) | Option Ex | 2,000 | 33.42 | 66,840 |
| 2020-03-09 | Sanofi | Sale | 128,914 | 489.65 | 63,123,126 |
| 2020-02-27 | Stahl Neil (EVP Research and Development) | Sale | 10,349 | 451.97 | 4,677,427 |
| 2020-02-26 | Landry Robert E (EVP Finance CFO) | Sale | 200 | 455.99 | 91,198 |
| 2020-02-26 | Stahl Neil (EVP Research and Development) | Option Ex | 25,000 | 52.03 | 1,300,750 |
| 2020-02-26 | Sing George L (Director) | Sale | 4,900 | 453.86 | 2,223,899 |
| 2020-02-26 | Sing George L (Director) | Option Ex | 2,500 | 33.42 | 83,550 |
| 2020-02-25 | Landry Robert E (EVP Finance CFO) | Sale | 214 | 448.67 | 96,016 |
| 2020-02-25 | Landry Robert E (EVP Finance CFO) | Option Ex | 1,000 | 272.70 | 272,700 |
| 2020-02-24 | Landry Robert E (EVP Finance CFO) | Option Ex | 1,000 | 272.70 | 272,700 |
| 2020-02-24 | Yancopoulos George (President and Chief Scientific) | Sale | 118,123 | 420.17 | 49,631,740 |
| 2020-02-24 | Brown Michael S (Director) | Sale | 2,000 | 419.01 | 838,030 |
| 2020-02-24 | Brown Michael S (Director) | Option Ex | 2,000 | 273.67 | 547,340 |
| 2020-02-13 | Landry Robert E (EVP Finance CFO) | Sale | 107 | 401.79 | 42,991 |
| 2020-02-13 | Tessier-lavigne Marc (Director) | Sale | 14,279 | 399.58 | 5,705,574 |
| 2020-02-13 | Tessier-lavigne Marc (Director) | Option Ex | 14,279 | 54.01 | 771,208 |
| 2020-02-12 | Landry Robert E (EVP Finance CFO) | Option Ex | 500 | 272.70 | 136,350 |
| 2020-02-07 | Goldstein Joseph L (Director) | Sale | 1,000 | 382.83 | 382,830 |
| 2020-01-27 | Murphy Andrew J (EVP Research) | Sale | 8,000 | 339.97 | 2,719,752 |
| 2020-01-24 | Fenimore Christopher R. (VP Controller) | Option Ex | 500 | 30.63 | 15,315 |
| 2020-01-02 | Sing George L (Director) | Sale | 15,000 | 371.98 | 5,579,700 |
| 2020-01-02 | Sing George L (Director) | Option Ex | 15,000 | 24.41 | 366,150 |
| 2019-12-20 | Fenimore Christopher R. (VP Controller) | Option Ex | 400 | 30.63 | 12,252 |
| 2019-12-13 | Fenimore Christopher R. (VP Controller) | Sale | 1,682 | 376.46 | 633,212 |
| 2019-12-13 | Brown Michael S (Director) | Sale | 4,000 | 373.84 | 1,495,360 |
| 2019-12-13 | Brown Michael S (Director) | Option Ex | 4,000 | 273.67 | 1,094,680 |
| 2019-12-13 | Vagelos P Roy (Chairman of the Board) | Sale | 51,842 | 376.42 | 19,514,417 |
| 2019-12-12 | Fenimore Christopher R. (VP Controller) | Option Ex | 3,100 | 52.03 | 161,293 |
| 2019-12-12 | Yancopoulos George (President and CSO) | Option Ex | 245,295 | 21.25 | 5,212,518 |
| 2019-12-12 | Schleifer Leonard S (President & CEO) | Option Ex | 312,400 | 21.25 | 6,638,500 |
| 2019-12-12 | Vagelos P Roy (Chairman of the Board) | Option Ex | 107,655 | 21.25 | 2,287,668 |
| 2019-11-27 | Goldstein Joseph L (Director) | Sale | 1,000 | 370.00 | 370,000 |
| 2019-11-27 | Goldstein Joseph L (Director) | Option Ex | 1,000 | 33.42 | 33,420 |
| 2019-11-26 | Stahl Neil (EVP Research and Development) | Sale | 4,006 | 364.40 | 1,459,774 |
| 2019-11-25 | Stahl Neil (EVP Research and Development) | Option Ex | 10,000 | 52.03 | 520,300 |
| 2019-11-25 | Vagelos P Roy (Chairman of the Board) | Sale | 22,149 | 362.53 | 8,029,699 |
| 2019-11-22 | Goldstein Joseph L (Director) | Sale | 1,000 | 360.00 | 360,000 |
| 2019-11-22 | Goldstein Joseph L (Director) | Option Ex | 1,000 | 33.42 | 33,420 |
| 2019-11-22 | Vagelos P Roy (Chairman of the Board) | Option Ex | 46,138 | 21.25 | 980,432 |
| 2019-11-21 | Goldstein Joseph L (Director) | Sale | 1,000 | 350.00 | 350,000 |
| 2019-11-21 | Goldstein Joseph L (Director) | Option Ex | 1,000 | 33.42 | 33,420 |
| 2019-11-12 | Brown Michael S (Director) | Sale | 4,500 | 349.00 | 1,570,500 |
| 2019-11-12 | Brown Michael S (Director) | Option Ex | 4,500 | 273.67 | 1,231,515 |
| 2019-11-08 | Stahl Neil (EVP Research and Development) | Sale | 7,364 | 336.81 | 2,480,239 |
| 2019-11-08 | Goldstein Joseph L (Director) | Sale | 1,000 | 340.44 | 340,440 |
| 2019-09-10 | Sanofi | Sale | 172,904 | 281.15 | 48,611,786 |
| 2019-05-24 | Vagelos P Roy (Chairman of the Board) | Option Ex | 153,792 | 21.25 | 3,268,080 |
| 2019-05-15 | Goldstein Joseph L (Director) | Sale | 1,000 | 305.93 | 305,930 |
| 2019-05-14 | Stahl Neil (EVP Research and Development) | Sale | 9,853 | 305.90 | 3,014,032 |
| 2019-05-13 | Stahl Neil (EVP Research and Development) | Option Ex | 25,000 | 52.03 | 1,300,750 |
| 2019-04-18 | Fenimore Christopher R. (VP Controller) | Option Ex | 350 | 21.25 | 7,437 |
| 2019-03-21 | Schleifer Leonard S (President & CEO) | Option Ex | 100 | 21.25 | 2,125 |
| 2019-03-08 | Sanofi | Sale | 131,115 | 412.17 | 54,041,276 |
| 2019-01-18 | Fenimore Christopher R. (VP Controller) | Option Ex | 150 | 21.25 | 3,187 |
| 2019-01-10 | Goldstein Joseph L (Director) | Sale | 1,791 | 410.00 | 734,310 |
| 2019-01-10 | Goldstein Joseph L (Director) | Option Ex | 1,791 | 273.67 | 490,142 |
| 2018-12-20 | Fenimore Christopher R. (VP Controller) | Sale | 1,848 | 358.88 | 663,215 |
| 2018-12-20 | Fenimore Christopher R. (VP Controller) | Option Ex | 675 | 21.25 | 14,343 |
| 2018-12-19 | Fenimore Christopher R. (VP Controller) | Option Ex | 3,450 | 52.03 | 179,503 |
| 2018-12-13 | Yancopoulos George (President and Chief Scientific) | Option Ex | 244,048 | 16.80 | 4,100,006 |
| 2018-12-13 | Schleifer Leonard S (President & CEO) | Option Ex | 312,500 | 16.80 | 5,250,000 |
| 2018-12-12 | Vagelos P Roy (Chairman of the Board) | Sale | 6 | 382.32 | 2,293 |
| 2018-09-28 | Goldstein Joseph L (Director) | Sale | 709 | 410.00 | 290,690 |
| 2018-09-28 | Goldstein Joseph L (Director) | Option Ex | 709 | 273.67 | 194,032 |
| 2018-09-27 | Goldstein Joseph L (Director) | Sale | 2,000 | 400.00 | 800,000 |
| 2018-09-27 | Goldstein Joseph L (Director) | Option Ex | 2,000 | 273.67 | 547,340 |
| 2018-09-27 | Brown Michael S (Director) | Sale | 2,000 | 392.89 | 785,774 |
| 2018-09-27 | Brown Michael S (Director) | Option Ex | 2,000 | 273.67 | 547,340 |
| 2018-09-24 | Goldstein Joseph L (Director) | Sale | 2,000 | 388.64 | 777,290 |
| 2018-09-24 | Goldstein Joseph L (Director) | Option Ex | 2,000 | 273.67 | 547,340 |
| 2018-09-06 | Sanofi | Sale | 104,552 | 406.68 | 42,519,207 |
| 2018-08-30 | Fenimore Christopher R. (VP Controller) | Option Ex | 50 | 21.25 | 1,062 |
| 2018-08-22 | Brown Michael S (Director) | Sale | 1,500 | 380.49 | 570,735 |
| 2018-08-22 | Brown Michael S (Director) | Option Ex | 1,500 | 177.82 | 266,730 |
| 2018-08-20 | Vagelos P Roy (Chairman of the Board) | Option Ex | 210 | 21.25 | 4,462 |
| 2018-08-02 | Goldstein Joseph L (Director) | Sale | 2,000 | 380.00 | 760,000 |
| 2018-08-02 | Goldstein Joseph L (Director) | Option Ex | 2,000 | 57.11 | 114,220 |
| 2018-07-10 | Vagelos P Roy (Chairman of the Board) | Sale | 74,670 | 367.96 | 27,475,573 |
| 2018-07-09 | Vagelos P Roy (Chairman of the Board) | Option Ex | 153,274 | 16.80 | 2,575,003 |
Insider trading activities including stock purchases, stock sales, and option exercises of REGN listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Regeneron Pharmaceuticals, Inc. (symbol REGN, CIK number 872589) see the Securities and Exchange Commission (SEC) website.